What do we know about micronutrients in critically ill patients? A narrative review

• Published in: JPEN. Journal of parenteral and enteral nutrition
• Main Authors: de Man, Angelique M. E., Stoppe, C., Koekkoek, W. A. C., Briassoulis, G., Subasinghe, S. D. L. P., Cobilinschi, C., Deane, A. M., Manzanares, W., Grințescu, I., Mirea, L., Roshdy, A., Cotoia, A., Bear, D. E., Boraso, S., Fraipont, V., Christopher, K. B., Casaer, M., Gunst, J., Pantet, O., Elhadi, M., Bolondi, G., Forceville, X., Angstwurm, M. W. A., Gurjar, M., Biondi, R., van Zanten, A. R. H., Berger, M. M.
• Format: Journal Article
• Language: English
• Published: SAGE Publications (UK and US) 18-11-2024
• Subjects: Food and Nutrition; Life Sciences; nutrition; micronutrients; critical illness; inflammation; oxidative stress
• ISSN: 0148-6071; 1941-2444; 1941-2444
• DOI: 10.1002/jpen.2700

Micronutrient (MN) status alterations (both depletion and deficiency) are associated with several complications and worse outcomes in critically ill patients. On the other side of the spectrum, improving MN status has been shown to be a potential co‐adjuvant therapy. This review aims to collect existing data to better guide research in the critical care setting. This narrative review was conducted by the European Society of Intensive Care Medicine Feeding, Rehabilitation, Endocrinology, and Metabolism MN group. The primary objective was to identify studies focusing on individual MNs in critically ill patients, selecting the MNs that appear to be most relevant and most frequently investigated in the last decade: A, B 1 , B 2 , B 3 , B 6 , folate, C, D, E, copper, iron, selenium, zinc, and carnitine. Given the limited number of interventional studies for most MNs, observational studies were included. For each selected MN, the review summarizes the main form and functions, special needs and risk factors, optimal treatment strategies, pharmacological dosing, and clinical implications all specific to critically ill patients. A rigorous rebalancing of research strategies and priorities is needed to improve clinical practice. An important finding is that high‐dose monotherapy of MNs is not recommended. Basal daily needs must be provided, with higher doses in diseases with known higher needs, and identified deficiencies treated. Finally, the review provides a list of ongoing trials on MNs in critically ill patients and identifies a priority list of future research topics.